Document:

DIRECTOR'S AGREEMENT
                              --------------------

     This Director's Agreement (this "Agreement") is made and entered into as of
the  28 day of April, 2004, (the "Effective Date"), by and between Warren C. Lau
(hereinafter  referred  to  as  "Director")  and  PharmaFrontiers  Corporation
(together  with  any successor to the business of PharmaFrontiers Corporation by
merger, consolidation or other form of business combination hereinafter referred
to  collectively  as  "PharmaFrontiers").

                                   WITNESSETH:

     WHEREAS,  the  shareholders  of  PharmaFrontiers  wish to elect Director to
serve  on  the Board of Directors (the "Board") of PharmaFrontiers, and Director
has  agreed  to  serve  at the pleasure of the shareholders and on the terms and
conditions  below;  and

     WHEREAS,  PharmaFrontiers'  success  requires  the  protection  of  its
intellectual  property,  proprietary  information  and  goodwill;

     NOW, THEREFORE, the parties hereto, intending to be legally bound, agree as
follows:

1.        Nomination  as  Director

     PharmaFrontiers  agrees  to  nominate  Director  for  election  by  the
shareholders of PharmaFrontiers as a director of PharmaFrontiers, and, upon such
election,  Director  agrees that Director will devote the amount of time, skill,
and  efforts during the term of this Agreement to the affairs of PharmaFrontiers
as  may  be reasonably requested and required of Director and in accordance with
the  duties and obligations imposed upon directors of corporations by applicable
lawCompensation

     As  compensation  for  serving as a member of the Board of PharmaFrontiers,
PharmaFrontiers  agrees  upon  the  execution  and delivery of this Agreement to
PharmaFrontiers,  to  issue  to  Director Twenty Thousand (20,000) shares of the
common  stock of PharmaFrontiers. In addition, PharmaFrontiers will pay Director
the  sum  of  $5,000.00  annually for each year Director serves as a Director of
PharmaFrontiers,  which  shall compensate Director for his expenses in attending
and participating in meetings of the Board. All compensation paid Director shall
be  subject to such payroll and withholding deductions as may be required by law
or  the  policies  of  PharmaFrontiers.

2.        Confidential  and  Proprietary  Information;  Documents

     3.1  PharmaFrontiers  shall provide Director with information deemed secret
and  confidential by PharmaFrontiers. Such secret or confidential information or
know-how  of  PharmaFrontiers  (referred  to  collectively  as  "Confidential
Information")  shall  include, without limitation, the following: the status and
plans  for  research  and  development;  materials,  cells,  tissues,  and other
biological samples and specimens; cell banking methods, apparatus, and services;
pending  and planned patent applications (until published by the Patent Office);
invention  disclosures;  research and technical data and information; methods of
creating,  preparing,  and  using  stem  cells  and  other biological materials;
license,  sublicense,  and  other

                                        1
<PAGE>
agreements  relating  to  intellectual  property rights; PharmaFrontiers' plans;
customer  or  contact  information;  contributor information; strategies, costs,
prices,  uses,  applications  of products and services; results of and data from
investigations or experiments; all apparatus, products, processes, compositions,
samples, formulas, computer programs, pricing policy, financial information, and
methods  of  doing  business;  policy  and/or  procedure  manuals,  training and
recruiting  procedures;  accounting  procedures;  the  status  and  content  of
PharmaFrontiers'  contracts  with  its  contributors,  clients,  and  customers;
PharmaFrontiers'  business philosophy, and servicing methods and techniques; all
at  any  time  used,  developed,  or  investigated by PharmaFrontiers, before or
during  the  term  of  this  Agreement, which are not generally available to the
public  or  which  are  maintained  as  confidential  by  PharmaFrontiers.

     3.2  Director recognizes and acknowledges that Director will have access to
certain  information of PharmaFrontiers that is confidential and proprietary and
constitutes  valuable  and  unique  property of PharmaFrontiers. Director agrees
that  Director  will not at any time, either during or subsequent to the term of
this  Agreement, disclose to others, use, copy or permit to be copied, except in
pursuance  of  Director's  duties  on behalf of PharmaFrontiers, its successors,
assigns  or  nominees,  or  as  required  by  the  order  of any tribunal having
jurisdiction  or  by  mandatory  provisions  of applicable law, any Confidential
Information  or know-how of PharmaFrontiers without the prior written consent of
the  Board of PharmaFrontiers. Director further agrees to maintain in confidence
any confidential information of third parties received as a result of Director's
relationship  with  PharmaFrontiers.

     3.3  Director  further  agrees to deliver to PharmaFrontiers promptly after
his  resignation,  removal  or failure to be nominated or elected as a member of
the  Board,  all biological materials correspondence, memoranda, notes, records,
drawings,  sketches,  plans,  customer, client and/or contributor lists, product
compositions,  or  other  documents  and  all  copies  thereof (all of which are
hereafter  referred  to  as  the  "Documents"),  made,  composed  or received by
Director, solely or jointly with others, and which are in Director's possession,
custody,  or  control  at  such  date and which are related in any manner to the
past,  present,  or  anticipated  business  of  PharmaFrontiers.

     3.4 Director further agrees that Director will not, during the term of this
Agreement,  and  on  behalf  of  PharmaFrontiers accept or agree to receive from
persons  not  employed  by  PharmaFrontiers,  any  confidential  information not
belonging to PharmaFrontiers, unless prior to such receipt or acceptance a valid
agreement  has  been  executed  between PharmaFrontiers and the disclosing party
that  states  that  PhalniaFrontiers  will not be in a confidential relationship
with the disclosing party. Director further agrees that Director will not use in
violation  of  any  confidentiality  obligation  binding  upon  Director  any
confidential  information  belonging  to  Director's  employer  or  any  former
employer,  or  any  other  third  parties.

     3.5  In the event of a breach or threatened breach of any of the provisions
of  Section  4,  or  any  breach  by  Director  of  his  fiduciary obligation to
PharmaFrontiers  and  its  shareholders, PharmaFrontiers shall be entitled to an
injunction  ordering the return of such Documents and any and all copies thereof
and restraining Director from using or disclosing, for Director's benefit or the
benefit  of others, in whole or in part, any Confidential Information, including
but  not  limited  to the Confidential Information which such Documents contain,
constitute,  or  embody.  Director

                                        2
<PAGE>
further  agrees that any breach or threatened breach of any of the provisions of
Section  4  would cause irreparable injury to PharmaFrontiers for which it would
have no adequate remedy at law. Nothing herein shall be construed as prohibiting
PharmaFrontiers  from  pursuing  any other remedies available to it for any such
breach  or  threatened  breach,  including  the  recovery  of  damages.

3.   Noncompetition/No-Hire  Agreement

     4.1 Director agrees that, from the Effective Date until a period of one (1)
year following the date of his resignation removal or failure to be nominated or
elected  as  a member of the Board, (the "Noncompetition Period"), Director will
not  directly or indirectly, either as an employee, employer, consultant, agent,
principal,  partner,  corporate officer, director, or in any other individual or
representative  capacity,  engage  or participate in any `"Competitive Business"
anywhere  in  the  United  States  of America, Canada or the European Union (the
"Noncompetition  Territory") As used herein, a "Competitive Business" is defined
as  any  business, including those relating to stem cells or cell banking, which
provides  the  same  or substantially the same products, services or licenses to
intellectual  property  rights,  in  whole  or  in  part,  as  are  provided  by
PharmaFrontiers  during  the  term  of  this  Agreement.

     4.2  Director  further  agrees  that  during  the Noncompetition Period and
within  the  Noncompetition Territory Director will not, directly or indirectly,
either  as  an  employee,  employer,  consultant,  agent,  principal,  partner,
corporate  officer,  director,  or  in  any  other  individual or representative
capacity, call on, solicit, recruit, or attempt to call on, solicit, or recruit,
or  attempt  to  hire  any  of  the  employees of PharmaFrontiers, regardless of
whether  for  the  benefit  of  the  Director  or for any other person, firm, or
corporation.

     4.3  Director  shall  not  during  the Noncompetition Period and within the
Noncompetition  Territory,  either  directly or indirectly (i) make known to any
Competitive  Business  the  names  and  addresses  of  any  of  PharmaFrontiers'
customers  or  contacts  or  any other information pertaining to such persons or
businesses  or  (ii)  call  on,  solicit,  or  take away, or attempt to call on,
solicit  or take away any of the customers of PharmaFrontiers with whom Director
became  acquainted  during  Director's  service  as a member of PharmaFrontiers'
Board,  regardless  of  whether for the benefit of the Director or for any other
person,  firm  or  corporation.

     4.4  Director  agrees that this Section is ancillary to this Agreement, and
Director  acknowledges  that the consideration given by PharmaFrontiers for this
Agreement  includes PharmaFrontiers' agreement to provide to the Director access
to the Confidential Information. Further, the existence of any claim or cause of
action of Director against PharmaFrontiers or any officer, director, or employee
of PharmaFrontiers, whether predicated on this Agreement or otherwise, shall not
constitute  a  defense  to  the  enforcement  by  PharmaFrontiers  of Director's
covenants  contained  in  this  Agreement.  In  addition,  this  Agreement shall
continue  to  be  binding  upon  Director  in  accordance  with  its  terms,
notwithstanding  the  termination  of  this  Agreement.

     4.5 Director agrees that Director's breach or violation, or threat thereof,
of  this  covenant  not to compete shall entitle PharmaFrontiers, as a matter of
right,  to  an  injunction  without the necessity of posting bond, issued by any
court  of  competent  jurisdiction,  restraining

                                        3
<PAGE>
any  further or continued breach or violation of this covenant. Such right to an
injunction shall be cumulative and in addition to, and not in lieu of, any other
remedies  to  which  PharmaFrontiers  may  show itself justly entitled. Further,
during  any  period  in  which  Director  is  in  breach of this covenant not to
compete,  the  time  period  of this covenant shall be extended for an amount of
time  that  Director  is  in  breach.

4.   Inventions  and  Other  Intellectual  Property

     5.1  Director  agrees  to  hold  in  complete  trust  for  the  benefit  of
PharmaFrontiers,  and  to  disclose  promptly  and  fully  to PharmaFrontiers in
writing,  and  hereby  assigns,  and  binds  Director's  heirs,  executors,
administrators,  and all legal representatives to assign, to PharmaFrontiers any
and  all  inventions,  discoveries, ideas, concepts, improvements, copyrightable
works,  biological  materials,  and  other  developments  (all  of the above are
collectively  referred  to as the "Developments") conceived, made, discovered or
developed  by  him,  solely  or  jointly  with  others,  during the term of this
Agreement,  whether  during  or  outside  of  usual working hours and whether on
PharmaFrontiers'  premises  or  not,  which  relate  in  any manner to the past,
present  or  anticipated business of PharmaFrontiers. The parties agree that, if
Director  is  an  inventor  as  determined by U.S. patent law for any invention,
Director shall be named as an inventor in connection with any patent application
therefor. Any and all such Developments shall be the sole and exclusive property
of  PharmaFrontiers, whether patentable, copyrightable, or neither, and Director
agrees  that  Director  will  assist  and  fully  cooperate  in  every  way,  at
PharmaFrontiers'  expense,  in  securing,  maintaining,  and  enforcing, for the
benefit  of  PharmaFrontiers or its designee, patents, copyrights or other types
of  proprietary or intellectual property protection for such Developments in any
and  all  countries.  Director  acknowledges  and  agrees  that any and all such
Developments  conceived,  created, or authored by him is a "work made for hire,"
as defined by the federal copyright laws, and therefore all copyrights in and to
such works are and will be owned by PharmaFrontiers. To the extent that Director
authors  any  copyrightable work in any medium during the term of this Agreement
which relates or pertains in any way to PharmaFrontiers or any of the operations
or activities of either and which was is held not a work made for hire, Director
hereby  assigns all right, title, and interest, including but not limited to all
rights  of copyright, in and to such works to PharmaFrontiers. Within six months
following the termination of this Agreement, and without limiting the generality
of  the  foregoing,  any  Development  of  the  Director  relating  to  any
PharmaFrontiers  subject  matter on which Director worked or was informed during
the term of this Agreement shall be conclusively presumed to have been conceived
and made prior to the termination of this Agreement (unless the Director clearly
proves that such Development was conceived and made following the termination of
this  Agreement),  and  shall  accordingly  belong,  and  be  assigned,  to
PharmaFrontiers  and  shall  be  subject  to  this  Agreement.

     5.2  Without  limiting  the  foregoing,  Director  agrees at the request of
PharmaFrontiers (but without additional compensation from PharmaFrontiers during
Director's  employment  by  PharmaFrontiers)  to  execute any and all papers and
perform  all  lawful  acts  which  PharmaFrontiers  deems  necessary  for  the
preparation,  filing,  prosecution,  and  maintenance of applications for United
States  and foreign letters patent, or for United States and foreign copyrights,
on  the  Developments,  and  to  execute  such  instruments  as are necessary or
convenient  to  assign  to PharmaFrontiers, its successors, assigns or nominees,
all  of  the  Director's  right,  title,

                                        4
<PAGE>
and  interest  in the Developments and the like, so as to establish, maintain or
perfect,  in  PharmaFrontiers,  its  successors, assigns or nominees, the entire
right,  title,  and  interest  to  the  Developments,  and  also  to execute any
instruments  necessary or which PharmaFrontiers may deem desirable it connection
with  any  continuation,  renewal  or  reissue thereof, or in the conduct of any
proceedings  or  litigation  in  regard  thereto.

     5.3  All  expenses incurred by the Director by reason of the performance of
any of the obligations set forth in this Section on Inventions shall be borne by
PharmaFrontiers.  Should  the  Director's  assistance  be  requested  by
PharmaFrontiers  after  termination  of  this  Agreement,  PharmaFrontiers would
compensate  the  Director  at  a  reasonable  rate.

5.   Conflicts  of  Interest

     6.1  In  keeping  with  Director's  fiduciary  duties  to  PharmaFrontiers,
Director agrees that Director shall not, directly or indirectly, become involved
in any conflict of interest, or upon discovery thereof, allow such a conflict to
continue. Moreover, Director agrees that Director shall promptly disclose to the
Board  of  PharmaFrontiers  any  facts  which  might  involve  any  reasonable
possibility of a conflict of interest as PharmaFrontiers is currently and in the
future  configured  and practicing business. Director shall maintain the highest
standards  of conduct, and shall not do anything likely to injure the reputation
or  goodwill  of  PharmaFrontiers,  or  embarrass  or otherwise generate adverse
publicity  for  or  bring  unwanted  attention  to  PharmaFrontiers.

     6.2  It is agreed that any direct or indirect interest in, connection with,
or  benefit  from  any  outside  activities, particularly commercial activities,
which  interest  might in any way adversely affect PharmaFrontiers or any of its
subsidiaries  or  affiliates,  involves  a  possible  conflict  of  interest.
Circumstances  in  which a conflict of interest on the part of Director would or
might  arise, and which should be reported immediately by Director to an officer
of PharmaFrontiers, include, without limitation, the following: (a) ownership of
a  material  interest  in,  acting in any capacity for, or accepting directly or
indirectly  any  payments,  services  or  loans  from  a  supplier,  contractor,
subcontractor,  customer  or  other  entity  with  which  PharmaFrontiers  does
business;  (b)  misuse of information or facilities to which Director has access
in  a  manner  which  will  be  detrimental  to  PharmaFrontiers'  interest; (c)
disclosure  or  other  misuse  of  information  of any kind obtained through the
Director's  connection  with  PharmaFrontiers;  (d)  acquiring  or  trading  in,
directly or indirectly, other properties or interests connected with the design,
manufacture  or  marketing  of  products  designed,  manufactured or marketed by
PharmaFrontiers;  (e)  the  appropriation  to  the  Director or the diversion to
others, directly or indirectly, of any opportunity in which it is known or could
reasonably  be anticipated that PharmaFrontiers would be interested; and (f) the
ownership,  directly  or  indirectly, of a material interest in an enterprise in
competition  with PharmaFrontiers or its dealers and distributors or acting as a
director,  officer,  partner,  consultant,  Director  or agent of any enterprise
which  is  in  competition  with PharmaFrontiers or its dealers or distributors.

                                        5
<PAGE>
6.   Prior Discoveries

     Director  has no unpatented inventions and discoveries made or conceived by
Director  prior  to  the  Effective  Date  that  relate  to stem cell isolation,
identification  and/or  expansion  and/or  cell  banking.

7.   Remedies

     Director  and  PharmaFrontiers  agree  that, because damages at law for any
breach  or  nonperformance of this Agreement by Director, while recoverable, are
and  will  be  inadequate,  this Agreement may be enforced in equity by specific
performance,  injunction,  accounting  or  otherwise.

8.   Miscellaneous

     9.1  This  Agreement  is made and entered into as of the Effective Date and
the rights and obligations of the parties hereto shall be binding upon the heirs
and  legal  representatives  of  the  Director and the successors and assigns of
PharmaFrontiers.  This  Agreement  may be assigned by PharmaFrontiers (including
assignment  by  operation  of  law  to  any  successor  to  the  business  of
PharmaFrontiers  by merger, consolidation or other business combination) without
the  consent  of Director but is personal to the Director and no rights, duties,
and  obligations  of  Director  hereunder may be assigned without the consent of
PharmaFrontiers  or  its  assigns,  which may be granted or withheld in its sole
discretion.

     9.2  No  waiver or non-action with respect to any breach by the other party
of any provision of this Agreement, nor the waiver or non-action with respect to
any breach of the provisions of similar agreements with other Directors shall be
construed  to  be  a  waiver of any succeeding breach of such provision, or as a
waiver  of  the  provision  itself.

     9.3 Should any portions hereof be held to be invalid or wholly or partially
unenforceable,  such  holding shall not invalidate or void the remainder of this
Agreement. The portions held to be invalid or unenforceable shall be revised and
reduced in scope so as to be valid and enforceable, or, if such is not possible,
then  such  portions  shall be deemed to have been wholly excluded with the same
force  and  effect  as  if  it  had  never  been  included  herein.

     9.4 Director's obligations under this Agreement to PharmaFrontiers shall
survive Director's resignation, removal or failure to be nominated or elected as
a member of the Board of
PharmaFrolitiers.

     9.5  This  Agreement  supersedes, replaces and merges any and all prior and
contemporaneous  understandings,  representations,  agreements  and  discussions
relating to the same or similar subject matter as that of this Agreement between
Director  and  PharmaFrontiers  and  constitutes  the  sole and entire agreement
between  the  Director and PharmaFrontiers with respect to the subject matter of
this  Agreement.

     9.6 The laws of the State of Texas, excluding any conflicts of law rule or
principle that might otherwise refer to the substantive law of another
jurisdiction, will govern the

                                        6
<PAGE>
interpretation,  validity  and  effect  of  this Agreement without regard to the
place of execution or the place for performance thereof, and PharmaFrontiers and
Director  agree that the state and federal courts in Harris County, Texas, shall
have  personal  jurisdiction and venue over PharmaFrontiers and Director to hear
all  disputes  arising  under  this  Agreement. This Agreement is to be at least
partially  performed  in  Harris  County,  Texas.

     9.7 All notices and other communications required or permitted hereunder or
necessary  or convenient in connection herewith shall be in writing and shall be
deemed  to  have  been  given  when mailed by registered mail or certified mail,
return  receipt  requested,  as  follows:

     If to PharmaFrontiers, to:

     Mr. Warren C. Lau
     Pha, maFrontiers Corporation
     10211 Silver Leaf Lane
     Tomball, Texas 77375

     If to Director, to:

     Mr. Warren C. Lau
     10211 Silver Leaf Lane
     Tomball, Texas 77375

or to such other addresses as either party may designate by notice to the other
party hereto in the manner specified in this section.

     9.8  This Agreement may not be changed or terminated orally, and no change,
termination  or  waiver  of  this  Agreement  or of any of the provisions herein
contained  shall  be  binding uniess made in writing and signed by both parties,
and in the case of PharmaFrontiers, by an authorized officer of PharmaFrontiers.
Any  change  or changes, from time to time, in Director's compensation shall not
be, nor be deemed to be, a change, termination or waiver of this Agreement or of
any  of  the  provisions  herein  contained.

By /s/ Warren C. Lau                   By /s/ Warren C. Lau
   ----------------------------------     --------------------------------------
     Warren C. Lau                          Warren C. Lau
     Printed Name                           Printed Name

                                        7
<PAGE><PAGE>

                                                                     EXHIBIT 4.1

NEITHER THESE SECURITIES NOR THE SECURITIES FOR WHICH THESE SECURITIES ARE
EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR
THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM
REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES
ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN
AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT AND IN COMPLIANCE WITH APPLICABLE STATE
SECURITIES OR BLUE SKY LAWS. THESE SECURITIES AND THE SECURITIES ISSUABLE UPON
EXERCISE OF THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE
MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

                                  SULPHCO, INC.

                           ADDITIONAL INVESTMENT RIGHT

Additional Investment Right No. [ ]                        Dated:  June __, 2004

         SulphCo, Inc., a Nevada corporation (the "COMPANY"), hereby certifies
that, for value received, [Name of Holder] or its registered assigns (the
"HOLDER"), is entitled to purchase from the Company (a) up to a total of [ ]
shares of common stock (the "COMMON Stock"), of the Company (each such share, an
"ADDITIONAL INVESTMENT RIGHT SHARE" and all such shares, the "ADDITIONAL
INVESTMENT RIGHT Shares") at an exercise price equal to $0.90 per share (as
adjusted from time to time as provided in SECTION 9, the "EXERCISE PRICE"), and
(b) only as part of and in connection with the purchase of the Additional
Investment Right Shares, warrants in the form attached to the Purchase Agreement
(as hereinafter defined) as EXHIBIT A to acquire up to 0.35 shares of Common
Stock for each Additional Investment Right Share purchased (the "ADDITIONAL
INVESTMENT RIGHT WARRANTS"), at any time and from time to time from and after
the date hereof and through and including the 180th Trading Day following the
Effective Date, but not including the Effective Date (the "EXPIRATION DATE"),
and subject to the following terms and conditions. This Additional Investment
Right (this "ADDITIONAL INVESTMENT RIGHT") is one of a series of similar
Additional Investment Rights issued pursuant to that certain Securities Purchase
Agreement, dated as of the date hereof, by and among the Company and the
Purchasers identified therein (the "PURCHASE AGREEMENT"). All such Additional
Investment Rights are referred to herein, collectively, as the "ADDITIONAL
INVESTMENT RIGHTS." Common Stock issuable upon exercise of the Additional
Investment Right Warrants shall be known herein as the "ADDITIONAL INVESTMENT
RIGHT WARRANT SHARES".

<PAGE>

         1. DEFINITIONS. In addition to the terms defined elsewhere in this
Additional Investment Right, capitalized terms that are not otherwise defined
herein have the meanings given to such terms in the Purchase Agreement.

         2. REGISTRATION OF ADDITIONAL INVESTMENT RIGHT. The Company shall
register this Additional Investment Right, upon records to be maintained by the
Company for that purpose (the "ADDITIONAL INVESTMENT RIGHT REGISTER"), in the
name of the record Holder hereof from time to time. The Company may deem and
treat the registered Holder of this Additional Investment Right as the absolute
owner hereof for the purpose of any exercise hereof or any distribution to the
Holder, and for all other purposes, absent actual notice to the contrary.

         3. REGISTRATION OF TRANSFERS. The Company shall register the assignment
and transfer of any portion of this Additional Investment Right in the
Additional Investment Right Register, upon surrender of this Additional
Investment Right, with the Form of Assignment attached hereto duly completed and
signed, to the Transfer Agent or to the Company at its address specified herein.
Upon any such registration or transfer, a new Additional Investment Right to
purchase Common Stock, in substantially the form of this Additional Investment
Right (any such new Additional Investment Right, a "NEW ADDITIONAL INVESTMENT
RIGHT"), evidencing the portion of this Additional Investment Right so
transferred shall be issued to the transferee and a New Additional Investment
Right evidencing the remaining portion of this Additional Investment Right not
so transferred, if any, shall be issued to the transferring Holder. The
acceptance of the New Additional Investment Right by the transferee thereof
shall be deemed the acceptance by such transferee of all of the rights and
obligations of a holder of an Additional Investment Right.

         4. EXERCISE AND DURATION OF ADDITIONAL INVESTMENT RIGHT.

             (a) This Additional Investment Right shall be exercisable by the
registered Holder at any time and from time to time on or after the date hereof
to and including the Expiration Date. At 6:30 P.M., New York City time on the
Expiration Date, the portion of this Additional Investment Right not exercised
prior thereto shall be and become void and of no value.

             (b) The Holder may exercise this Additional Investment Right by
delivering to the Company (i) the original Additional Investment Right and an
exercise notice, in the form attached hereto (the "EXERCISE NOTICE"),
appropriately completed and duly signed, and (ii) payment of the Exercise Price
for the number of Additional Investment Right Shares and Additional Investment
Right Warrants as to which this Additional Investment Right is being exercised,
and the date such items are delivered to the Company (as determined in
accordance with the notice provisions hereof) is an "EXERCISE DATE." Execution
and delivery of the Exercise Notice shall have the same effect as cancellation
of the original Additional Investment Right and issuance of a New Additional
Investment Right evidencing the right to purchase the remaining number of
Additional Investment Right Shares and Additional Investment Right Warrants.

                                       2
<PAGE>

         5. DELIVERY OF ADDITIONAL INVESTMENT RIGHT SHARES AND ADDITIONAL
INVESTMENT RIGHT WARRANTS.

             (a) Upon exercise of this Additional Investment Right, the Company
shall promptly (but in no event later than three Trading Days after the Exercise
Date) issue or cause to be issued and cause to be delivered to or upon the
written order of the Holder and in such name or names as the Holder may
designate, a certificate for the Additional Investment Right Shares and
Additional Investment Right Warrants issuable upon such exercise, free of
restrictive legends unless a registration statement covering the resale of the
Additional Investment Right Shares, the Additional Investment Right Warrant
Shares and naming the Holder as a selling stockholder thereunder is not then
effective and the Additional Investment Right Shares and Additional Investment
Right Warrant Shares, respectively, are not freely transferable without volume
restrictions pursuant to Rule 144 under the Securities Act. The Holder, or any
Person so designated by the Holder to receive Additional Investment Right Shares
and Additional Investment Right Warrants, shall be deemed to have become holder
of record of such Additional Investment Right Shares and Additional Investment
Right Warrants as of the Exercise Date. The Company shall, upon request of the
Holder, use its best efforts to deliver Additional Investment Right Shares and
Additional Investment Right Warrants hereunder electronically through the
Depository Trust Corporation or another established clearing corporation
performing similar functions.

             (b) This Additional Investment Right is exercisable, either in its
entirety or, from time to time, for a portion of the number of Additional
Investment Right Shares and Additional Investment Right Warrants. Upon surrender
of this Additional Investment Right following one or more partial exercises, the
Company shall issue or cause to be issued, at its expense, a New Additional
Investment Right evidencing the right to purchase the remaining number of
Additional Investment Right Shares and Additional Investment Right Warrants.

             (c) In addition to any other rights available to a Holder, if the
Company fails to deliver to the Holder a certificate representing Additional
Investment Right Shares on the third Trading Day after the date on which
delivery of such certificate is required by this Additional Investment Right or
any Additional Investment Right Warrant, and if after such third Trading Day the
Holder purchases (in an open market transaction or otherwise) shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the Additional
Investment Right Shares that the Holder anticipated receiving from the Company
(a "BUY-IN"), then the Company shall, within three Trading Days after the
Holder's request and in the Holder's discretion, either (i) pay cash to the
Holder in an amount equal to the Holder's total purchase price (including
brokerage commissions, if any) for the shares of Common Stock so purchased (the
"BUY-IN PRICE"), at which point the Company's obligation to deliver such
certificate (and to issue such Common Stock) shall terminate, or (ii) promptly
honor its obligation to deliver to the Holder a certificate or certificates
representing such Common Stock and pay cash to the Holder in an amount equal to
the excess (if any) of the Buy-In Price over the product of (A) such number of
shares of Common Stock, times (B) the Closing Price on the date of the event
giving rise to the Company's obligation to deliver such certificate.

                                       3
<PAGE>

             (d) The Company's obligations to issue and deliver Additional
Investment Right Shares and Additional Investment Right Warrants in accordance
with the terms hereof are absolute and unconditional, irrespective of any action
or inaction by the Holder to enforce the same, any waiver or consent with
respect to any provision hereof, the recovery of any judgment against any Person
or any action to enforce the same, or any setoff, counterclaim, recoupment,
limitation or termination, or any breach or alleged breach by the Holder or any
other Person of any obligation to the Company or any violation or alleged
violation of law by the Holder or any other Person, and irrespective of any
other circumstance which might otherwise limit such obligation of the Company to
the Holder in connection with the issuance of Additional Investment Right Shares
and Additional Investment Right Warrants. Nothing herein shall limit a Holder's
right to pursue any other remedies available to it hereunder, at law or in
equity including, without limitation, a decree of specific performance and/or
injunctive relief with respect to the Company's failure to timely deliver
certificates representing shares of Common Stock upon exercise of the Additional
Investment Right as required pursuant to the terms hereof.

         6. CHARGES, TAXES AND EXPENSES. Issuance and delivery of certificates
for shares of Common Stock and Additional Investment Right Warrants upon
exercise of this Additional Investment Right shall be made without charge to the
Holder for any issue or transfer tax, withholding tax, transfer agent fee or
other incidental tax or expense in respect of the issuance of such certificates,
all of which taxes and expenses shall be paid by the Company; provided, however,
that the Company shall not be required to pay any tax which may be payable in
respect of any transfer involved in the registration of any certificates for
Additional Investment Right Shares, Additional Investment Rights or any
Additional Investment Right Warrants in a name other than that of the Holder or
an Affiliate thereof. The Holder shall be responsible for all other tax
liability that may arise as a result of holding or transferring this Additional
Investment Right or receiving Additional Investment Right Shares and Additional
Investment Right Warrants upon exercise hereof.

         7. REPLACEMENT OF ADDITIONAL INVESTMENT RIGHT. If this Additional
Investment Right is mutilated, lost, stolen or destroyed, the Company shall
issue or cause to be issued in exchange and substitution for and upon
cancellation hereof, or in lieu of and substitution for this Additional
Investment Right, a New Additional Investment Right, but only upon receipt of
evidence reasonably satisfactory to the Company of such loss, theft or
destruction and customary and reasonable indemnity, if requested. Applicants for
a New Additional Investment Right under such circumstances shall also comply
with such other reasonable regulations and procedures and pay such other
reasonable third-party costs as the Company may prescribe.

         8. RESERVATION OF ADDITIONAL INVESTMENT RIGHT SHARES AND ADDITIONAL
INVESTMENT RIGHT WARRANT SHARES. The Company covenants that it will at all times
reserve and keep available out of the aggregate of its authorized but unissued
and otherwise unreserved Common Stock, solely for the purpose of enabling it to
issue Additional Investment Right Shares upon exercise of this Additional
Investment Right and Additional Investment Right Warrants as provided herein or
in the Additional Investment Right Warrant Shares upon exercise of the
Additional Investment Right Warrants as provided in the Additional Investment
Right Warrants, the number of Additional Investment Right Shares which are then
issuable and deliverable upon the exercise of this entire Additional Investment
Right and the number of Additional Investment Right Warrant Shares issuable and
deliverable upon the exercise of any Additional Investment Right Warrants, free
from preemptive rights or any other contingent purchase rights of persons other
than the Holder (after giving effect to the adjustments and restrictions of
SECTION 9, if any). The Company covenants that all Additional Investment Right
Shares and Additional Investment Right Warrant Shares so issuable and
deliverable shall, upon issuance and the payment of the applicable Exercise
Price in accordance with the terms hereof, or the Additional Investment Right

                                       4
<PAGE>

Warrants be duly and validly authorized, issued and fully paid and
nonassessable. The Company will take all such action as may be necessary to
assure that such shares of Common Stock may be issued as provided herein and
further to the Additional Investment Right Warrants without violation of any
applicable law or regulation, or of any requirements of any securities exchange
or automated quotation system upon which the Common Stock may be listed.

         9. CERTAIN ADJUSTMENTS. The Exercise Price and number of Additional
Investment Right Shares issuable upon exercise of this Additional Investment
Right are subject to adjustment from time to time as set forth in this SECTION
9. The exercise price and number of this Additional Investment Right Warrant
Shares issuable upon exercise of the Additional Investment Right Warrants shall
be subject to adjustment from time to time as set forth in the Warrants issued
by the Company on the date hereof pursuant to the Purchase Agreement.

             (a) STOCK DIVIDENDS AND SPLITS. If the Company, at any time while
this Additional Investment Right is outstanding, (i) pays a stock dividend on
its Common Stock or otherwise makes a distribution on any class of capital stock
that is payable in shares of Common Stock, (ii) subdivides outstanding shares of
Common Stock into a larger number of shares, or (iii) combines outstanding
shares of Common Stock into a smaller number of shares, then in each such case
the Exercise Price shall be multiplied by a fraction of which the numerator
shall be the number of shares of Common Stock outstanding immediately before
such event and of which the denominator shall be the number of shares of Common
Stock outstanding immediately after such event. Any adjustment made pursuant to
clause (i) of this paragraph shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or
distribution, and any adjustment pursuant to clauses (ii) or (iii) of this
paragraph shall become effective immediately after the effective date of such
subdivision or combination.

             (b) PRO RATA DISTRIBUTIONS. If the Company, at any time while this
Additional Investment Right is outstanding, distributes to holders of Common
Stock (i) evidences of its indebtedness, (ii) any security (other than a
distribution of Common Stock covered by the preceding paragraph), (iii) rights
or warrants to subscribe for or purchase any security, or (iv) any other asset
(in each case, "DISTRIBUTED Property"), then in each such case the Exercise
Price in effect immediately prior to the record date fixed for determination of
stockholders entitled to receive such distribution shall be adjusted (effective
on such record date) to equal the product of such Exercise Price times a
fraction of which the denominator shall be the average of the Closing Prices for
the five Trading Days immediately prior to (but not including) such record date
and of which the numerator shall be such average less the then fair market value
of the Distributed Property distributed in respect of one outstanding share of
Common Stock, as determined by the Company's independent certified public
accountants that regularly examine the financial statements of the Company (an
"APPRAISER"). In such event, the Holder, after receipt of the determination by
the Appraiser, shall have the right to select an additional appraiser (which
shall be a nationally recognized accounting firm), in which case such fair
market value shall be deemed to equal the average of the values determined by
each of the Appraiser and such appraiser. As an alternative to the foregoing
adjustment to the Exercise Price, at the request of the Holder delivered before
the 90th day after such record date, the Company will deliver to such Holder,
within five Trading Days after such request (or, if later, on the effective date
of such distribution), the Distributed Property that such Holder would have been
entitled to receive in respect of the Additional Investment Right Shares for
which this Additional Investment Right could have been exercised immediately

                                       5
<PAGE>

prior to such record date. If such Distributed Property is not delivered to a
Holder pursuant to the preceding sentence, then upon expiration of or any
exercise of the Additional Investment Right that occurs after such record date,
such Holder shall remain entitled to receive, in addition to the Additional
Investment Right Shares otherwise issuable upon such exercise (if applicable),
such Distributed Property.

             (c) FUNDAMENTAL TRANSACTIONS. If, at any time while this Additional
Investment Right is outstanding, (i) the Company effects any merger or
consolidation of the Company with or into another Person, (ii) the Company
effects any sale of all or substantially all of its assets in one or a series of
related transactions, (iii) any tender offer or exchange offer (whether by the
Company or another Person) is completed pursuant to which holders of Common
Stock are permitted to tender or exchange their shares for other securities,
cash or property, or (iv) the Company effects any reclassification of the Common
Stock or any compulsory share exchange pursuant to which the Common Stock is
effectively converted into or exchanged for other securities, cash or property
(other than as a result of a subdivision or combination of shares of Common
Stock covered by Section 9(a) above) (in any such case, a "FUNDAMENTAL
TRANSACTION"), then the Holder shall have the right thereafter to receive, upon
exercise of this Additional Investment Right, the same amount and kind of
securities, cash or property as it would have been entitled to receive upon the
occurrence of such Fundamental Transaction if it had been, immediately prior to
such Fundamental Transaction, the holder of the number of Additional Investment
Right Shares then issuable upon exercise in full of this Additional Investment
Right (the "ALTERNATE CONSIDERATION"). The aggregate Exercise Price for this
Additional Investment Right will not be affected by any such Fundamental
Transaction, but the Company shall apportion such aggregate Exercise Price among
the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as
to the Alternate Consideration it receives upon any exercise of this Additional
Investment Right following such Fundamental Transaction. At the Holder's
request, any successor to the Company or surviving entity in such Fundamental
Transaction shall issue to the Holder a new warrant consistent with the
foregoing provisions and evidencing the Holder's right to purchase the Alternate
Consideration for the aggregate Exercise Price upon exercise thereof. The terms
of any agreement pursuant to which a Fundamental Transaction is effected shall
include terms requiring any such successor or surviving entity to comply with
the provisions of this paragraph (c) and insuring that the Additional Investment
Right (or any such replacement security) will be similarly adjusted upon any
subsequent transaction analogous to a Fundamental Transaction. If any
Fundamental Transaction constitutes or results in a Change of Control, then at
the request of the Holder delivered before the 90th day after such Fundamental
Transaction, the Company (or any such successor or surviving entity) will
purchase the Additional Investment Right from the Holder for a purchase price,
payable in cash within five Trading Days after such request (or, if later, on
the effective date of the Fundamental Transaction), equal to the Black Scholes
value of the remaining unexercised portion of this Additional Investment Right
on the date of such request.

                                       6
<PAGE>

             (d) NUMBER OF ADDITIONAL INVESTMENT RIGHT SHARES. Simultaneously
with any adjustment to the Exercise Price pursuant to paragraphs (a) or (b) of
this Section, the number of Additional Investment Right Shares that may be
purchased upon exercise of this Additional Investment Right shall be increased
or decreased proportionately, so that after such adjustment the aggregate
Exercise Price payable hereunder for the increased or decreased number of
Additional Investment Right Shares shall be the same as the aggregate Exercise
Price in effect immediately prior to such adjustment.

             (e) CALCULATIONS. All calculations under this SECTION 9 shall be
made to the nearest cent or the nearest 1/100th of a share, as applicable. The
number of shares of Common Stock outstanding at any given time shall not include
shares owned or held by or for the account of the Company, and the disposition
of any such shares shall be considered an issue or sale of Common Stock.

             (f) NOTICE OF ADJUSTMENTS. Upon the occurrence of each adjustment
pursuant to this SECTION 9, the Company at its expense will promptly compute
such adjustment in accordance with the terms of this Additional Investment Right
and prepare a certificate setting forth such adjustment, including a statement
of the adjusted Exercise Price and adjusted number or type of Additional
Investment Right Shares or other securities issuable upon exercise of this
Additional Investment Right (as applicable), describing the transactions giving
rise to such adjustments and showing in detail the facts upon which such
adjustment is based. Upon written request, the Company will promptly deliver a
copy of each such certificate to the Holder and to the Company's Transfer Agent.

             (g) NOTICE OF CORPORATE EVENTS. If the Company (i) declares a
dividend or any other distribution of cash, securities or other property in
respect of its Common Stock, including without limitation any granting of rights
or warrants to subscribe for or purchase any capital stock of the Company or any
Subsidiary, (ii) authorizes or approves, enters into any agreement contemplating
or solicits stockholder approval for any Fundamental Transaction or (iii)
authorizes the voluntary dissolution, liquidation or winding up of the affairs
of the Company, then the Company shall deliver to the Holder a notice describing
the material terms and conditions of such transaction, at least 20 calendar days
prior to the applicable record or effective date on which a Person would need to
hold Common Stock in order to participate in or vote with respect to such
transaction, and the Company will take all steps reasonably necessary in order
to insure that the Holder is given the practical opportunity to exercise this
Additional Investment Right prior to such time so as to participate in or vote
with respect to such transaction; provided, however, that the failure to deliver
such notice or any defect therein shall not affect the validity of the corporate
action required to be described in such notice.

         10. PAYMENT OF EXERCISE PRICE. The Holder shall pay the Exercise Price
in immediately available funds.

         11. LIMITATION ON EXERCISE. (a) Notwithstanding anything to the
contrary contained herein, the number of shares of Common Stock that may be
acquired by the Holder upon any exercise of this Additional Investment Right (or
otherwise in respect hereof) shall be limited to the extent necessary to insure
that, following such exercise (or other issuance), the total number of shares of
Common Stock then beneficially owned by such Holder and its Affiliates and any
other Persons whose beneficial ownership of Common Stock would be aggregated
with the Holder's for purposes of Section 13(d) of the Exchange Act, does not
exceed 4.999% (the "MAXIMUM PERCENTAGE") of the total number of issued and

                                       7
<PAGE>

outstanding shares of Common Stock (including for such purpose the shares of
Common Stock issuable upon such exercise). For such purposes, beneficial
ownership shall be determined in accordance with Section 13(d) of the Exchange
Act and the rules and regulations promulgated thereunder. Each delivery of an
Exercise Notice hereunder will constitute a representation by the Holder that it
has evaluated the limitation set forth in this paragraph and determined that
issuance of the full number of Additional Investment Right Shares requested in
such Exercise Notice is permitted under this paragraph. The Company's obligation
to issue shares of Common Stock in excess of the limitation referred to in this
Section shall be suspended (and shall not terminate or expire notwithstanding
any contrary provisions hereof) until such time, if any, as such shares of
Common Stock may be issued in compliance with such limitation. By written notice
to the Company, the Holder may waive the provisions of this Section or increase
or decrease the Maximum Percentage to any other percentage specified in such
notice, but (i) any such waiver or increase will not be effective until the 61st
day after such notice is delivered to the Company, and (ii) any such waiver or
increase or decrease will apply only to the Holder and not to any other holder
of Additional Investment Rights.

             (b) Notwithstanding anything to the contrary contained herein, if
the Trading Market is the NASDAQ SmallCap Market or any other market or exchange
with similar applicable rules, then the maximum number of shares of Common Stock
that the Company may issue pursuant to the Transaction Documents at an effective
purchase price less than the Closing Price on the Trading Day immediately
preceding the Closing Date equals 19.99% cap shares (the "ISSUABLE MAXIMUM"),
unless the Company obtains shareholder approval in accordance with the rules and
regulations of such Trading Market. If, at the time any Holder requests an
exercise of any of the Additional Investment Rights, the Actual Minimum
(excluding any shares issued or issuable at an effective purchase price in
excess of the Closing Price on the Trading Day immediately preceding the Closing
Date) exceeds the Issuable Maximum (and if the Company has not previously
obtained the required shareholder approval), then the Company shall issue to the
Holder requesting such exercise a number of shares of Common Stock not exceeding
such Holder's pro-rata portion of the Issuable Maximum (based on such Holder's
share (vis-a-vis other Holders) of the aggregate purchase price paid under the
Purchase Agreement and taking into account any Additional Investment Rights
Shares and any Additional Investment Right Warrant Shares previously issued to
such Holder), and the remainder of the Additional Investment Rights Shares and
Additional Investment Right Warrant Shares issuable in connection with such
exercise or conversion (if any) shall constitute "Excess Shares" pursuant to
Section 12(c) below. For the purposes hereof, "ACTUAL MINIMUM" shall mean, as of
any date, the maximum aggregate number of shares of Common Stock then issued or
potentially issuable in the future pursuant to the Transaction Documents,
including any Additional Investment Right Shares issuable upon exercise in full
of all Additional Investment Rights, ignoring any limits on the number of shares
of Common Stock that may be owned by a Holder at any one time.

             (c) In the event that any Holder's receipt of shares of Common
Stock upon exercise of this Additional Investment Right is restricted based on
the Issuable Maximum, the Company shall either: (i) use its best efforts to
obtain the required shareholder approval necessary to permit the issuance of
such Excess Shares as soon as is reasonably possible, but in any event not later
than the 60th day after the event giving rise to such Excess Shares, or (ii)
within five Trading Days after such event, pay cash to such Holder, as
liquidated damages and not as a penalty, in an amount equal to the difference
between the Black Scholes value of this Additional Investment Right assuming the

                                       8
<PAGE>

limitations in Section 12(b) were not applicable and the Black Scholes value of
this Additional Investment Right after giving effect to the limitations in
Section 12(b), measured as of the date of such event or, if greater, the date of
payment (such difference, the "CASH AMOUNT"). If the Company elects the first
option under the preceding sentence and the Company fails to obtain the required
shareholder approval on or prior to the 60th day after such event, then within
three Trading Days after such 60th day, the Company shall pay the Cash Amount to
such Holder, as liquidated damages and not as a penalty.

         12. FRACTIONAL SHARES. The Company shall not be required to issue or
cause to be issued fractional Additional Investment Right Shares or Additional
Investment Right Warrants to purchase fractional Additional Investment Right
Warrant Shares on the exercise of this Additional Investment Right. If any
fraction of a Additional Investment Right Share or if any Additional Investment
Right Warrant to purchase a fraction of an Additional Investment Right Warrant
Share would, except for the provisions of this Section, be issuable upon
exercise of this Additional Investment Right, the number of Additional
Investment Right Shares and/or Additional Investment Right Warrant Shares
issuable upon exercise of the Additional Investment Right Warrants, as the case
may be, to be issued will be rounded up to the nearest whole share or right to
purchase the nearest whole share, as the case may be.

         13. NOTICES. Any and all notices or other communications or deliveries
hereunder (including without limitation any Exercise Notice) shall be in writing
and shall be deemed given and effective on the earliest of (i) the date of
transmission, if such notice or communication is delivered via facsimile at the
facsimile number specified in this Section prior to 6:30 p.m. (New York City
time) on a Trading Day, (ii) the next Trading Day after the date of
transmission, if such notice or communication is delivered via facsimile at the
facsimile number specified in this Section on a day that is not a Trading Day or
later than 6:30 p.m. (New York City time) on any Trading Day, (iii) the Trading
Day following the date of mailing, if sent by a nationally recognized overnight
courier service, or (iv) upon actual receipt by the party to whom such notice is
required to be given. The address for such notices or communications shall be as
set forth in the Purchase Agreement.

         14. ADDITIONAL INVESTMENT RIGHT AGENT. The Company shall serve as
additional investment right agent under this Additional Investment Right. Upon
30 days' notice to the Holder, the Company may appoint a new additional
investment right agent. Any corporation into which the Company or any new
additional investment right agent may be merged or any corporation resulting
from any consolidation to which the Company or any new additional investment
right agent shall be a party or any corporation to which the Company or any new
additional investment right agent transfers substantially all of its corporate
trust or shareholders services business shall be a successor additional
investment right agent under this Additional Investment Right without any
further act. Any such successor additional investment right agent shall promptly
cause notice of its succession as additional investment right agent to be mailed
(by first class mail, postage prepaid) to the Holder at the Holder's last
address as shown on the Additional Investment Right Register.

                                       9
<PAGE>

         15. MISCELLANEOUS.

             (a) Subject to the restrictions on transfer set forth on the first
page hereof, this Additional Investment Right may be assigned by the Holder.
This Additional Investment Right may not be assigned by the Company except to a
successor in the event of a Fundamental Transaction. This Additional Investment
Right shall be binding on and inure to the benefit of the parties hereto and
their respective successors and assigns. Subject to the preceding sentence,
nothing in this Additional Investment Right shall be construed to give to any
Person other than the Company and the Holder any legal or equitable right,
remedy or cause of action under this Additional Investment Right. This
Additional Investment Right may be amended only in writing signed by the Company
and the Holder and their successors and assigns.

             (b) The Company will not, by amendment of its governing documents
or through any reorganization, transfer of assets, consolidation, merger,
dissolution, issue or sale of securities or any other voluntary action, avoid or
seek to avoid the observance or performance of any of the terms of this
Additional Investment Right, but will at all times in good faith assist in the
carrying out of all such terms and in the taking of all such action as may be
necessary or appropriate in order to protect the rights of the Holder against
impairment. Without limiting the generality of the foregoing, the Company (i)
will not increase the par value of any Additional Investment Right Shares or
Additional Investment Right Warrant Shares above the amount payable therefor on
such exercise, (ii) will take all such action as may be reasonably necessary or
appropriate in order that the Company may validly and legally issue fully paid
and nonassessable Additional Investment Right Shares or Additional Investment
Right Warrant Shares on the exercise of this Additional Investment Right and the
Additional Investment Right Warrants, respectively, and (iii) will not close its
shareholder books or records in any manner which interferes with the timely
exercise of this Additional Investment Right.

             (C) GOVERNING LAW; VENUE; WAIVER OF JURY TRIAL. ALL QUESTIONS
CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS
ADDITIONAL INVESTMENT RIGHT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. EACH PARTY HEREBY IRREVOCABLY
SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN
THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE
HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY
OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE
TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT
IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT
TO THE JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS
IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND
CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY
MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY
(WITH EVIDENCE OF DELIVERY) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES
TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD
AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN
SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER
PERMITTED BY LAW. THE COMPANY HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.

                                       10
<PAGE>

             (d) The headings herein are for convenience only, do not constitute
a part of this Additional Investment Right and shall not be deemed to limit or
affect any of the provisions hereof.

             (e) In case any one or more of the provisions of this Additional
Investment Right shall be invalid or unenforceable in any respect, the validity
and enforceability of the remaining terms and provisions of this Additional
Investment Right shall not in any way be affected or impaired thereby and the
parties will attempt in good faith to agree upon a valid and enforceable
provision which shall be a commercially reasonable substitute therefor, and upon
so agreeing, shall incorporate such substitute provision in this Additional
Investment Right.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK,
                             SIGNATURE PAGE FOLLOWS]

                                       11
<PAGE>

         IN WITNESS WHEREOF, the Company has caused this Additional Investment
Right to be duly executed by its authorized officer as of the date first
indicated above.

                                            SULPHCO, INC.

                                            By:
                                                --------------------------------
                                            Name: Rudolf W. Gunnerman
                                            Title:   Chief Executive Officer

                                       12
<PAGE>

                             FORM OF EXERCISE NOTICE

(To be executed by the Holder to exercise the right to purchase shares of Common
Stock under the foregoing Additional Investment Right)

To:  SulphCo, Inc.

The undersigned is the Holder of Additional Investment Right No. _______ (the
"ADDITIONAL INVESTMENT RIGHT") issued by SulphCo, Inc., a Nevada corporation
(the "COMPANY"). Capitalized terms used herein and not otherwise defined have
the respective meanings set forth in the Additional Investment Right.

1.       The Additional Investment Right is currently exercisable to purchase a
         total of ______________ Additional Investment Right Shares.

2.       The undersigned Holder hereby exercises its right to purchase
         _________________ Additional Investment Right Shares pursuant to the
         Additional Investment Right and Additional Investment Right Warrants
         exercisable for ______ shares of Common Stock.

3.       The Holder intends that payment of the Exercise Price shall be made in
         immediately available funds, and shall pay the sum of $____________ to
         the Company in accordance with the terms of the Additional Investment
         Right.

4.       Pursuant to this exercise, the Company shall deliver to the holder
         _______________ Additional Investment Right Shares and Additional
         Investment Right Warrants exercisable for ______ shares of Common
         Stock.

5.       Following this exercise, the Additional Investment Right shall be
         exercisable to purchase a total of ______________ Additional Investment
         Right Shares and Additional Investment Right Warrants exercisable for
         _____ shares of Common Stock .

Dated: ______________, ____            Name of Holder:

                                       (Print)__________________________________

                                       By:______________________________________
                                       Name:____________________________________
                                       Title:___________________________________

                                    (Signature must conform in all respects to
                                    name of holder as specified on the face of
                                    the Additional Investment Right)

<PAGE>

                               FORM OF ASSIGNMENT

 [To be completed and signed only upon transfer of Additional Investment Right]

         FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers
unto ________________________________ the right represented by the within
Additional Investment Right to purchase ____________ shares of Common Stock and
warrants to purchase shares of the Common Stock of SulphCo, Inc. to which the
within Additional Investment Right relates and appoints ________________
attorney to transfer said right on the books of SulphCo, Inc. with full power of
substitution in the premises.

Dated: _______________, ____

                                    ____________________________________________
                                    (Signature must conform in all respects to
                                    name of holder as specified on the face of
                                    the Additional Investment Right)

                                    ____________________________________________
                                    Address of Transferee

                                    ____________________________________________

                                    ____________________________________________

In the presence of:

___________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}]]